Head and Neck Cancer Market Size is estimated to grow at a CAGR of 8.5% during the forecast period for 2025-2034.
According to the study published in NCBI (2014), head and neck cancer (HNC) is the sixth most common cancer worldwide, with an estimated 630,000 new cases every year. Specifically, this type of cancer includes tumors of the oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity. Tobacco and alcohol consumption is strongly associated with head and neck cancer.
Multiple factors that drive the head and neck cancer market include the increasing combination therapies for the management of head & neck cancer, rising prevalence of head and neck cancer, increasing adoption of advanced medical technologies, reduction in medical errors in cancer care, various government initiatives for various cancer therapy developments, and increasing awareness among people regarding the advanced cancer treatments. In addition, risk factors such as growth in cigarette smoking, alcohol intake & tobacco use are expected to fuel the market growth.
However, the high cost of treatments, the side effects of available therapies, and the lack of health coverage act as major restraints of this market.
The head and neck cancer market has been segmented on the basis of product and region. The products segment comprises of cytotoxic agents [Antimetabolites (Abitrexate/ Mexate/ Folex (methotrexate), hydrea (hydroxyurea), antitubulins, taxotere (docetaxel), others (Platinum Agents, Fluoropyrimidines), Platinol (cisplatin), 5-fluorouracil (5-FU)], EGFR Inhibitors [Erbitux (cetuximab), Vectibi (panitumumab), Theracim/Theraloc (nimotuzumab)], EGFR Inhibitors (TKIs) [Tarceva (erlotinib), Iressa (gefitinib), Tykerb/Tyverb (lapatinib)], PD1 Inhibitors [Keytruda (pembrolizumab), Opdivo (nivolumab)], Pipeline Drugs [EGFR Inhibitors (mAbs) (Vectibix (panitumumab)), PDL1 Inhibitors (Imfinzi (durvalumab), Bavencio (avelumab)), CTLA4 Inhibitors (Yervoy (ipilimumab), Tremelimumab)]. At regional level, the head and neck cancer market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The North American region is projected to hold the major market share in 2024, followed by Europe, Asia-Pacific, and Rest-of-the-World.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 8.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Products |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Advaxis, Inc. (US), Amgen, Inc. (US), AstraZeneca plc (UK), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.) (Japan), Cel-Sci Corporation (US), Five Prime Therapeutics, Inc. (US), GlaxoSmithKline plc (UK), Incyte Corporation (US), IRX Therapeutics, Inc. (US), MacroGenics, Inc. (US), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer, Inc., Roche Holdings AG (Genentech) (Switzerland), Viracta Therapeutics (US) among others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell Head and Neck Cancer Market Snapshot
Chapter 4. Global Cell Head and Neck Cancer Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Clinical Trial/Pipeline Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 3: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Cytotoxic Agents
5.2.1.1. Antimetabolites
5.2.1.1.1. Abitrexate/ Mexate/ Folex (methotrexate)
5.2.1.1.2. Hydrea (hydroxyurea)
5.2.1.2. Antitubulins
5.2.1.2.1. Taxotere (docetaxel)
5.2.1.3. Others (Platinum Agents, Fluoropyrimidines)
5.2.1.3.1. Platinol (cisplatin)
5.2.1.3.2. 5-fluorouracil (5-FU)
5.2.2. EGFR Inhibitors (mAbs)
5.2.2.1. Erbitux (cetuximab)
5.2.2.2. Vectibix (panitumumab)
5.2.2.3. Theracim/Theraloc (nimotuzumab)
5.2.3. EGFR Inhibitors (TKIs)
5.2.3.1. Tarceva (erlotinib)
5.2.3.1.1. Iressa (gefitinib)
5.2.3.2. Tykerb/Tyverb (lapatinib)
5.2.4. PD1 Inhibitors
5.2.4.1. Keytruda (pembrolizumab)
5.2.4.2. Opdivo (nivolumab)
5.2.5. Pipeline Drugs (Late-stage)
5.2.5.1. EGFR Inhibitors (mAbs)
5.2.5.1.1. Vectibix (panitumumab)
5.2.5.2. PDL1 Inhibitors
5.2.5.2.1. Imfinzi (durvalumab)
5.2.5.2.2. Bavencio (avelumab)
5.2.5.3. CTLA4 Inhibitors
5.2.5.3.1. Yervoy (ipilimumab)
5.2.5.3.2. Tremelimumab
Chapter 6. Cell Head and Neck Cancer Market Segmentation 5: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
6.1.2. North America Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
6.2. Europe
6.2.1. Europe Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.2.2. Europe Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.3. Asia Pacific
6.3.1. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.3.2. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts by Types, 2021-2034
6.3.3. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.4. Latin America
6.4.1. Latin America Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.4.2. Latin America Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.5. Middle East & Africa
6.5.1. Middle East & Africa Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.5.2. Middle East & Africa Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Advaxis, Inc.
7.2.2. Amgen, Inc.
7.2.3. AstraZeneca plc
7.2.4. Boehringer Ingelheim GmbH
7.2.5. Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.)
7.2.6. Cel-Sci Corporation
7.2.7. Five Prime Therapeutics, Inc.
7.2.8. GlaxoSmithKline plc
7.2.9. Incyte Corporation
7.2.10. IRX Therapeutics, Inc.
7.2.11. MacroGenics, Inc.
7.2.12. Merck KGaA
7.2.13. Novartis AG
7.2.14. Pfizer, Inc.
7.2.15. Roche Holdings AG (Genentech)
7.2.16. Viracta Therapeutics
7.2.17. Other Prominent Players
Global Head and Neck Cancer Market, by Products
Global Head And Neck Cancer Market, by Region
\North America Head and Neck Cancer Market, by Country
Europe Head and Neck Cancer Market, by Country
Asia Pacific Head and Neck Cancer Market, by Country
Latin America Head and Neck Cancer Market, by Country
Middle East & Africa Head and Neck Cancer Market, by Country
Competitive Landscape
Other Prominent Players
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
